Seeking Alpha

Market Vectors Pharmaceutical ETF (PPH)

Show Summaries  |  Hide Summaries
  • Apr. 4, 2014, 1:12 PM
  • Sep. 23, 2011, 1:53 PM
    Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy.
    | 1 Comment
  • Aug. 1, 2011, 3:56 PM
    Citi lowers its price target on Auxilium Pharmaceuticals (AUXL -6.6%) to $22 from $27 saying expectations on revenue from the firm's Xiaflex are too high. Earlier the firm issued its own downward guidance on FY11 revenue derived from the drug to a range of $45M-$50M from $50M-$60M.
    | Comment!
  • Jul. 8, 2011, 8:59 AM
    Geron (GERN) releases positive data from a clinical trial of its human embryonic stem cell-based therapy. JPMorgan initiates coverage with an Overweight rating. Shares +5.4% premarket.
    | Comment!
  • Jun. 30, 2011, 11:56 AM
    Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively.
    | Comment!
Visit Seeking Alpha's
PPH vs. ETF Alternatives
PPH Description
The Market Vectors® Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors US Listed Pharmaceutical 25 Index (MVPPHTR). The Index is a rules-based index intended to track the overall performance of 25 of the largest U.S. listed, publicly traded pharmaceutical companies.
See more details on sponsor's website
Sector: Healthcare
Country: United States
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub